celecoxib has been researched along with Multiple Sclerosis in 2 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor." | 5.39 | A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation. ( Alloza, I; Chiba, A; Di Penta, A; Miyake, S; Vandenbroeck, K; Villoslada, P; Wyssenbach, A; Yamamura, T, 2013) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 5.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| "Celecoxib is a selective cyclooxygenase-2 (COX2) inhibitor." | 1.39 | A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation. ( Alloza, I; Chiba, A; Di Penta, A; Miyake, S; Vandenbroeck, K; Villoslada, P; Wyssenbach, A; Yamamura, T, 2013) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 1.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Penta, A | 1 |
| Chiba, A | 1 |
| Alloza, I | 1 |
| Wyssenbach, A | 1 |
| Yamamura, T | 1 |
| Villoslada, P | 1 |
| Miyake, S | 1 |
| Vandenbroeck, K | 1 |
| Cocco, G | 1 |
2 other studies available for celecoxib and Multiple Sclerosis
| Article | Year |
|---|---|
A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation.
Topics: Animals; Astrocytes; Axons; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Cytokines; Dise | 2013 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors | 2012 |